Effect of Modified Erchentang on CC16, SP-D and HAT and HDAC in Patients at Acute Exacerbation Stage of COPD

SHANG Li-zhi; JI Shu; XIE Wen-ying; XUE Hong-li; LIU Zhi-yong; LIU Tan; ZHANG Jing; DU Hong-yan; LI Jin-jing; SUN Chun-yang; LIU Xiao-hui; LIANG Juan-juan; ZHANG Miao; WANG Yi

doi:10.13422/j.cnki.syfjx.2017100163

您当前的位置：

首页 >

文章列表页 >

Effect of Modified Erchentang on CC16, SP-D and HAT and HDAC in Patients at Acute Exacerbation Stage of COPD

更新时间：2024-01-04

- Effect of Modified Erchentang on CC16, SP-D and HAT and HDAC in Patients at Acute Exacerbation Stage of COPD
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 23, Issue 10, Pages: 163-170(2017)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2017100163
  CLC： R285.6
- Published：2017
- 稿件说明：
移动端阅览
SHANG Li-zhi, JI Shu, XIE Wen-ying, et al. Effect of Modified Erchentang on CC16, SP-D and HAT and HDAC in Patients at Acute Exacerbation Stage of COPD[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(10): 163-170.
DOI：

SHANG Li-zhi, JI Shu, XIE Wen-ying, et al. Effect of Modified Erchentang on CC16, SP-D and HAT and HDAC in Patients at Acute Exacerbation Stage of COPD[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(10): 163-170. DOI： 10.13422/j.cnki.syfjx.2017100163.

摘要

目的：观察二陈汤加味对COPD急性期加重期（acute exacerbation period of COPD，AECOPD）患者血浆、呼气冷凝液（exhale breath condensat，EBC）中克拉拉细胞蛋白（Clara cell protein，CC16），肺表面活性蛋白-D（pulmonary surfactant associated protein-D，SP-D）含量及外周血单个核细胞（peripheral blood mononuclear cell，PBMC）中组蛋白乙酰基转移酶（histone acetyl transferase，HAT）及组蛋白去乙酰基酶（histone deacetylase，HDAC）活性的影响，评价二陈汤加味对AECOPD的作用及机制。方法：选取符合纳入标准AECOPD患者200例，随机分成对照组和治疗组，每组100例。两组均在西医常规治疗的基础上，对照组给予安慰剂，治疗组接受二陈汤加味治疗，疗程14 d。检测肺功能，酶联免疫吸附试验（ELISA）法测定血浆，EBC中白细胞介素-17（interleukin-17，IL-17），C反应蛋白（C-reactive protein，CRP），CC16，SP-D及PBMC中HDAC1，HDAC2浓度。酶联免疫荧光法测定PBMC中HAT及HDAC活性。结果：与对照组治疗后比较，治疗组血浆及EBC中CRP，IL-17，CC16和SP-D水平均明显降低（P<0.05，P<0.01），PBMC中HAT活性明显降低（P<0.05），HDAC活性，HDAC2含量均明显增高（P<0.05）。结论：二陈汤加味可能调整HAT/HDAC的平衡，发挥抗炎作用，保护气道和肺的结构与功能。

Abstract

Objective: To study of the effect and mechanism of modified Erchentang on Clara cell protein (CC16)

pulmonary surfactant associated protein-D (SP-D)

histone acetyl transferase (HAT) and histone deacetylase (HDAC) in patients at acute aggravating stage of COPD. Method: Totally 200 cases at acute exacerbation period of COPD (AECOPD) were randomly divided into modified Erchentang group and placebo-controlled group

with 100 cases in each group. In addition to western drugs

modified Erchentang was also used in the modified Erchentang group

and placebo was also used in control group for 14 days. Their pulmonary function was detected

and euzyme-linked immunosorbent assay was used to determine the levels of C-reactive protein (CRP)

interleukin-17 (IL-17)

CC16

SP-D

HDAC1 and HAD2 in plasma and exhaled breath condensate of all groups. The activities of HAT and HDAC were determinate by enzyme-linked immune fluorescence. Result: The activity of HDAC2 was higher significantly

but the levels of CRP

IL-17

CC16 and SP-D (P<0.05

P<0.01) in plasma and exhaled breath condensate

and the activity of HAT were significantly decreased in treatment group with modified Erchentang

compared with those in control group. Conclusion: Modified Erchentang may have an effect on COPD by adjusting the HAT/HDAC

reducing levels of CRP

IL-17

CC16 and SP-D

preventing inflammation progress and improving the structure and function of respiratory system and lungs.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Modified Erchentang on Expressions of Chemokine Receptor CXCR1/2 and CXCL8 in Patients with AECOPD

Effect of Modified Erchentang on Hif-1 and Sirtuins 1 in Patients with COPD

Mechanism of Modified Erchentang on COPD Inflammation Based on TNF-α/TNFR1/RIPKs Pathway

Modified Erchentang Alleviates Inflammation in Chronic Obstructive Pulmonary Disease via Midkine/Notch2/Hey1 Signaling Pathway in Rats

Clinical Effect of Erchentang and Bixie Fenqingyin Combined on Patients with Acute Cerebral Infarction with Hyperuricemia with Syndrome of Phlegm and Blood Stasis Blocking Collaterals

Related Author

Li-zhi SHANG

Shu JI

Yao-yang LI

Meng-di MAO

Guo-qiang WANG

Long-tao SHI

Guang-yuan ZHANG

Li-li XU

Related Institution

Henan University of Chinese Medicine

Henan Provincial Second People's Hospital

Shanghai Yangzhi Rehabilitation Hospital（Shanghai Sunshine Rehabilitation Center）， Tongji University School of Medicine

Shuguang Hospital Affiliated to Shanghai University of TCM

Putuo Hospital，Shanghai University of Tranditional Chinese Medicine（TCM）

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰